Abstract 2142P
Background
The improvement in cancer survival, allows for higher ICU admission ratios. A pilot program in our center instituted weekly meetings between ICU and Oncology aimed at determining the appropriate level of care for patients admitted in Oncology. Objective: establish which factors predict decision-making regarding the level of care and admission to the ICU and benefit of intensive care.
Methods
Single-center prospective observational study. Recruitment between September-2021 and July-2022. Statistical analysis: descriptive study, multivariate logistic regression for decision of admission in ICU. We performed a second subsequent analysis with the paired propensity score matching technique. Survival analysis: Kaplan-Meier (KM) curves and log-Rank test. Significance level: p ≤ 0.05.
Results
411 patients. 60.3% male; median age: 64 years. Most prevalent tumor: lung (26.3%). Stage IV: 72.5%. The most common reason for admission in Oncology: infectious pathology (33.8%). 54.7% were considered ICU candidates, while only 17 patients (4.1%) finally required intensive care. In a multivariate logistic regression model, ECOG 0-1 (OR 2.7; IC95%: 1.6-4.5), absence of peritoneal carcinomatosis (OR 4.5; IC95%: 2.0-9.9), and intentionality of treatment (adjuvant, neoadjuvant or first-line) (OR 5.4; IC 95%: 3.1-9.5) predicted decision of admission to the ICU. Age > 65 years (OR 0.35; IC 95%: 0.2-0.6) and poor symptom control as cause of admission in Oncology (OR 0.16; 95%: 0.03-0.93) were negative factors for ICU admission. By means of paired propensity analysis (Nearest-neighbor model), the sample was reduced to 172 patients and there was only statistical significance in the univariate analysis for intentionality of treatment and for treatment with immunotherapy (IT). After a median follow-up of 4 months, median survival was significantly different (p< 0.05) for patients who were not ICU candidates (2.5 months), patients who were admitted to the ICU (10 months) and patients who were ICU candidates but did not require admission (12.5 months).
Conclusions
Multidisciplinary decision-making may contribute to individualize the level of intensive care for Oncology patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
F. Ayala de la Pena
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Advisory Board: Leo Pharma, Sanofi, Lundbeck, Angelini. All other authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07